[ad_1]
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. (“Curis” or the “Company”) (NASDAQ:CRIS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Curis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On April 4, 2022, Curis announced “that the US Food and Drug Administration (FDA) has placed a partial clinical hold on the Company’s TakeAim Leukemia Phase 1/2a study (NCT04278768)” for “orally-administered emavusertib (CA-4948) as monotherapy and in combination with azacitidine…
Full story available on Benzinga.com
[ad_2]
Source link
